How Global Trends Help or Hamper Pharma Business

Amid global politics, supply chain vulnerabilities, and innovation opportunities, the pharmaceutical industry is constantly reshaped

The pharmaceutical industry worldwide operates at the intersection of science, policy, and macroeconomic trends. In the 2020s, supply chain disruptions, trade conflicts, regional instabilities, and evolving regulations are reshaping everything from drug ingredient sourcing to clinical trial management and R&D investment. Some global trends act as tailwinds, stimulating investment, innovation, and local capacity. Others come as headwinds, including increased costs and uncertainty. Understanding both is essential for strategic planning.

Domestic versus Global Dynamics

The COVID-19 pandemic highlighted the fragility of global medicine supply chains. Many nations introduced policies to increase domestic control over critical drugs and vaccines. The U.S. imports a significant portion of its active pharmaceutical ingredients (APIs) from abroad¹. Similarly, the European Union has initiatives to reshore production of essential drugs². These policy initiatives present both opportunities and challenges. Companies offering modular, localized manufacturing, such as portable biomanufacturing units, stand to benefit. But duplication of production lines and varying quality standards reduces efficiency. Therefore, policies focused on domestic production may increase short-term costs but could encourage more sustainable and innovative manufacturing in the long term. Trade and collaboration policies in major pharmaceutical-producing regions are shaping the global biotech industry. Shifts in supply chains and research collaboration can affect drug development timelines and innovation ecosystems^3,4. These dynamics also encourage domestic investment in advanced biotech infrastructure and workforce development, creating opportunities for innovation. In the coming years, the global biotech landscape may consist of several semi-independent innovation hubs with differing regulatory, data, and IP standards.

Energy, IP, and Trade Frameworks: The Impact on Pharma

Regional instabilities and global energy fluctuations affect production costs and supply continuity. Many chemical intermediates and solvents essential for drug synthesis are energy intensive⁵. Energy price volatility has previously delayed production of pharmaceutical components⁶. Companies that adopt energy efficient facilities and viable green chemistry innovations are likely to outperform their competitors as global energy variability continues. Moreover, stable intellectual property (IP) systems are central to pharmaceutical innovation. Different countries and trade blocs are adjusting IP rules to balance access and innovation incentives⁷. These changes create both challenges and opportunities. Companies that can navigate differentiated IP frameworks and adapt their commercial strategies will be better positioned for global growth.

Regulatory Considerations in a Global Industry

Regulatory authorities are increasingly attentive to cross-border compliance, data integrity, and cybersecurity. Programs monitoring foreign manufacturing compliance have expanded⁸. New cloud-based compliance solutions ensure data protection and regulatory alignment⁹. Emerging requirements for localized clinical data and digital records may affect global clinical trial design and R&D timelines.

Regional partnerships aim to co-develop vaccines and biologics in areas closer to where demand is greatest. Changes in regulatory policies are also accelerating innovation, as exemplified in the shift towards promoting New Approach Technologies (NAMs, e.g. in vitro assays, organ-on-chip, computational toxicology). These will require validation before regulators accept them as an alternative to animal testing. Geopolitics matters, as countries have differing levels of acceptance for NAMs. For example, a recent UK policy paper proposes substantial reductions in animal testing and the adoption of alternative models by 2030.¹⁰

Equally, the EU has pushed strongly for NAMs under REACH and animal-testing bans, whereas the U.S. and Japan have been more cautious, and often require additional bridging studies. Pharma companies operating globally must navigate this patchwork, which can be slowed or complicated by trade tensions or differing regulatory philosophies. Companies are presently investing in digital twins, AI-driven process control, and decentralized manufacturing.¹¹ How NAM adoption following validation could intersect with geopolitical challenges that affect the pharmaceutical business model is explored in the table below:

Pharma firms that treat global trends as strategic factors, not just compliance challenges, will likely lead the next wave of innovation. The future of this industry is shaped not only by science and business strategy, but also by global economic, regulatory, and supply chain trends. Those who can best anticipate risks and leverage opportunities will thrive; those who do not could face business model disruption.

References:
1.    U.S. Food and Drug Administration. Drug Shortages: Root Causes and Potential Solutions. 2020. https://www.fda.gov/drugs/drug-shortages/report-drug-shortages-root-causes-and-potential-solutions
2.    European Commission. Critical Medicines Alliance. 2024. https://health.ec.europa.eu/health-emergency-preparedness-and-response-hera/overview/critical-medicines-alliance_en
3.    US Pharmacopeia. From risk to resilience: transform your supply chain. 2024. https://www.usp.org/supply-chain/medicine-supply-map
4.    Federal Register. Controls on Certain Laboratory Equipment and Related Technology To Address Dual Use Concerns About Biotechnology. 2025. https://www.federalregister.gov/documents/2025/01/16/2025-00723/controls-on-certain-laboratory-equipment-and-related-technology-to-address-dual-use-concerns-about
5.    International Energy Agency. World Energy Outlook. 2024. https://www.iea.org/reports/world-energy-outlook-2024
6.    World Bank. Commodity Markets Outlook. 2023. https://openknowledge.worldbank.org/entities/publication/0e4e7e1e-6db9-4011-b179-806d28aa0b91
7.    IQVIA. Global Use of Medicines 2025: Outlook to 2029. 2025. https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/the-global-use-of-medicines-outlook-through-2029
8.    U.S. Food and Drug Administration. Bioresearch Monitoring Inspections Metrics. 2024. https://www.fda.gov/science-research/clinical-trials-and-human-subject-protection/bimo-inspection-metrics
9.    European Medicines Agency. Cloud Strategy. 2022. https://www.ema.europa.eu/en/documents/other/european-medicines-agency-cloud-strategy-accelerating-innovation-and-digitalisation-better-public-and-animal-health-outcomes_en.pdf
10.    UK Government. Replacing animals in science strategy. 2025. https://www.gov.uk/government/publications/deleted-replacing-animals-in-science-strategy/replacing-animals-in-science-a-strategy-to-support-the-development-validation-and-uptake-of-alternative-methods
11.    Shariatifar M, Rizi MS, Sotudeh-Gharebagh R, et al. On digital twins in bioprocessing: Opportunities and limitations. Process Biochem., 2025, 156:274-299. doi: 10.1016/j.procbio.2025.05.023